INTRODUCTION: Lipoprotein-associated phospholipase A2 (Lp-PLA(2)) has been consistently associated with cardiovascular disease (CVD) risk factors and predictive of CVD outcomes; furthermore, it is consistently higher among type 2 diabetics than nondiabetics. However, the relationships of circulating Lp-PLA(2) mass and activity with incident type 2 diabetes mellitus have not been examined. Therefore, the purpose of this study was to determine the association of Lp-PLA(2) mass and activity with type 2 diabetes among older adults. METHODS: We conducted analyses of Lp-PLA(2) and prevalent and incident diabetes among 5474 men and women from the Cardiovascular Health Study (1989-2007). Lp-PLA(2) mass and activity were measured in baseline plasma. Diabetes status was ascertained annually with medication inventories and repeated blood glucose measurements. Generalized linear and Cox proportional hazards models were used to adjust for confounding factors including body mass index and inflammation. RESULTS: At baseline, the top two quintiles of Lp-PLA(2) activity were significantly associated with prevalent type 2 diabetes with a multivariable relative risk = 1.35 [95% confidence interval (CI) = 1.11-1.63] for quintile 4, and relative risk = 1.33 (95% CI = 1.07-1.66) for quintile 5. Among participants free of diabetes at baseline, we found a significant positive association with both the homeostatic model assessment for insulin resistance and β-cell function per SD increase in Lp-PLA(2) activity (P values for both <0.01). In prospective analyses, the risk of incident type 2 diabetes was significantly higher among those in the highest quintile of Lp-PLA(2) activity [multivariable hazard ratio = 1.45 (95% CI = 1.01-2.07)] compared with the lowest quintile. Lp-PLA(2) mass was not significantly associated with incident type 2 diabetes. DISCUSSION: Lp-PLA(2) activity is positively associated with insulin resistance and predicts incident type 2 diabetes among older adults independent of multiple factors associated with diabetes pathogenesis.
INTRODUCTION:Lipoprotein-associated phospholipase A2 (Lp-PLA(2)) has been consistently associated with cardiovascular disease (CVD) risk factors and predictive of CVD outcomes; furthermore, it is consistently higher among type 2 diabetics than nondiabetics. However, the relationships of circulating Lp-PLA(2) mass and activity with incident type 2 diabetes mellitus have not been examined. Therefore, the purpose of this study was to determine the association of Lp-PLA(2) mass and activity with type 2 diabetes among older adults. METHODS: We conducted analyses of Lp-PLA(2) and prevalent and incident diabetes among 5474 men and women from the Cardiovascular Health Study (1989-2007). Lp-PLA(2) mass and activity were measured in baseline plasma. Diabetes status was ascertained annually with medication inventories and repeated blood glucose measurements. Generalized linear and Cox proportional hazards models were used to adjust for confounding factors including body mass index and inflammation. RESULTS: At baseline, the top two quintiles of Lp-PLA(2) activity were significantly associated with prevalent type 2 diabetes with a multivariable relative risk = 1.35 [95% confidence interval (CI) = 1.11-1.63] for quintile 4, and relative risk = 1.33 (95% CI = 1.07-1.66) for quintile 5. Among participants free of diabetes at baseline, we found a significant positive association with both the homeostatic model assessment for insulin resistance and β-cell function per SD increase in Lp-PLA(2) activity (P values for both <0.01). In prospective analyses, the risk of incident type 2 diabetes was significantly higher among those in the highest quintile of Lp-PLA(2) activity [multivariable hazard ratio = 1.45 (95% CI = 1.01-2.07)] compared with the lowest quintile. Lp-PLA(2) mass was not significantly associated with incident type 2 diabetes. DISCUSSION: Lp-PLA(2) activity is positively associated with insulin resistance and predicts incident type 2 diabetes among older adults independent of multiple factors associated with diabetes pathogenesis.
Authors: Karl Winkler; Bernhard R Winkelmann; Hubert Scharnagl; Michael M Hoffmann; Andrea Busse Grawitz; Markus Nauck; Bernhard O Böhm; Winfried März Journal: Circulation Date: 2005-02-14 Impact factor: 29.690
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Lloyd E Chambless; Merle Myerson; Kenneth K Wu; A Richey Sharrett; Eric Boerwinkle Journal: Arch Intern Med Date: 2005-11-28
Authors: Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman Journal: Circulation Date: 2005-02-08 Impact factor: 29.690
Authors: Li Li; David J Ruau; Chirag J Patel; Susan C Weber; Rong Chen; Nicholas P Tatonetti; Joel T Dudley; Atul J Butte Journal: Sci Transl Med Date: 2014-04-30 Impact factor: 17.956
Authors: Julia Seyfarth; Thomas Reinehr; Annika Hoyer; Christina Reinauer; Christina Bächle; Beate Karges; Ertan Mayatepek; Michael Roden; Sabine E Hofer; Susanna Wiegand; Joachim Woelfle; Wieland Kiess; Joachim Rosenbauer; Reinhard W Holl; Thomas Meissner Journal: J Inherit Metab Dis Date: 2017-10-13 Impact factor: 4.982
Authors: Jose Luis Sánchez-Quesada; Irene Vinagre; Elena De Juan-Franco; Juan Sánchez-Hernández; Rosa Bonet-Marques; Francisco Blanco-Vaca; Jordi Ordóñez-Llanos; Antonio Pérez Journal: Cardiovasc Diabetol Date: 2013-08-05 Impact factor: 9.951
Authors: Anja Böhm; Anna Halama; Tobias Meile; Marty Zdichavsky; Rainer Lehmann; Cora Weigert; Andreas Fritsche; Norbert Stefan; Alfred Königsrainer; Hans-Ulrich Häring; Martin Hrabě de Angelis; Jerzy Adamski; Harald Staiger Journal: PLoS One Date: 2014-04-02 Impact factor: 3.240
Authors: Peter J Meikle; Gerard Wong; Christopher K Barlow; Jacquelyn M Weir; Melissa A Greeve; Gemma L MacIntosh; Laura Almasy; Anthony G Comuzzie; Michael C Mahaney; Adam Kowalczyk; Izhac Haviv; Narelle Grantham; Dianna J Magliano; Jeremy B M Jowett; Paul Zimmet; Joanne E Curran; John Blangero; Jonathan Shaw Journal: PLoS One Date: 2013-09-27 Impact factor: 3.240